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We investigated olfactory function and its relation to cardiac
123I-metaiodobenzylguanidine (MIBG) uptake in 15 patients
with drug induced parkinsonism (DIP). The mean Cross Cultural
Smell Identification (CCSI) score was significantly greater in
patients with DIP than in those with Parkinson’s disease (PD: 6.9
(1.6) vs 4.4 (2.2); p,0.001); however, the mean CCSI score in
patients with DIP was not significantly different from controls.
One patient with DIP, whose CCSI score was significantly
reduced, also exhibited decreased cardiac MIBG uptake. DIP
patients with CCSI scores within the normal range had normal
cardiac MIBG uptake. Our study suggests that an olfactory
function test may be a useful tool for detecting DIP unrelated to
PD and for identifying patients with DIP who have subclinical
PD.
T
he clinical manifestations of drug induced parkinsonism
(DIP), which constitutes 15–60% of all parkinsonism cases,
are very similar to those of Parkinson’s disease (PD).1 2
Parkinsonian symptoms usually resolve within a few weeks
after the patient stops taking the offending drugs. However,
DIP is not always reversible; it has been reported that PD can
develop after apparent recovery from DIP and that PD can
persist and eventually worsen after discontinuation of the
offending drug.3–5
It is well known that patients with PD have markedly
impaired olfactory function.6 Furthermore, an impairment in
olfactory function is an early manifestation of the neuropatho-
logical process in PD, and it may precede the development of
parkinsonian motor symptoms.7 Recently, we have shown that
the cardiac 123I-metaiodobenzylguanidine (MIBG) uptake ratio
is a useful tool for the differentiation of DIP from PD and the
identification of DIP patients in whom the offending drugs may
have unmasked clinical manifestations of parkinsonism.8
In this study, we investigated olfactory function in patients
with DIP to assess its usefulness in differentiating PD from DIP,
and evaluated its relation to cardiac MIBG uptake in patients
with DIP.
PATIENTS AND METHODS
We prospectively enrolled 15 patients with DIP, 24 patients
with PD and 15 healthy controls. All patients were referred to
our hospital consecutively for the treatment or diagnostic
evaluation of parkinsonism. DIP was diagnosed using the
following three criteria: (1) presence of at least two of the four
cardinal signs (tremor, rigidity, bradykinesia and impaired
postural reflexes), (2) absence of a history of extrapyramidal
disorders before treatment with the offending drug and (3)
onset of symptoms during the course of treatment with the
offending drug. All patients with DIP were examined every
month for at least 3 months after withdrawal of the offending
drug. None of the patients with DIP in the previous study8 were
included in this study. PD was diagnosed according to the UK
Parkinson’s Disease Society Brain Bank clinical diagnosis
criteria.9 The clinical stages of parkinsonism were assessed
according to the classification of Hoehn and Yahr.10
Subjects suffering from otorhinolaryngeal disorders (upper
respiratory tract infection or sinonasal disease, as established by
otorhinolaryngologist),11 those exhibiting evidence of dementia
(Mini-Mental State Examination score ,27)12 and current
smokers13 were excluded from the study. None of the patients
had a history of neuropathy, previous relevant cardiac disease
or severe head injury. Routine chest radiography and electro-
cardiography revealed no abnormalities. Age matched subjects
with no history of neurological or heart diseases were enrolled
as a control group. All subjects provided written informed
consent, and the study was approved by our hospital ethics
committee.
To assess olfactory function, the Cross Cultural Smell
Identification (CCSI) test,14 a widely used test of odour
identification involving a scratch and sniff test of 12 micro-
encapsulated odorants with a forced choice of four alternatives
per item, was administrated to all subjects. For the cardiac
uptake experiments, 123I-MIBG (111 mBq) was injected intra-
venously into each subject, and cardiac uptake was imaged 3 h
later, using a dual head c camera system (MultiSPECT III,
Siemens Medical Systems, Inc., Iselin, New Jersey, USA). The
regions of interest were the whole heart and the mediastinum
of the front image, and the ratio of 123I-MIBG uptake in the
heart to that in the mediastinum (H/M ratio) was calculated.
The Mann–Whitney U and Fisher’s exact tests were used to
compare the means of groups in pairs when the variables were
continuous and categorical, respectively. A p value of ,0.05
was regarded as statistically significant. The statistical analyses
were performed using commercially available software (SPSS,
version 12.0).
RESULTS
There was no significant difference in age between patients
with DIP (68.7 (6.9)), patients with PD (64.4 (10.7)) and
controls (63.7 (10.1)). The female to male ratio was not
significantly different between patients with DIP (80%),
patients with PD (50%) and controls (56%). There was no
significant difference in the duration of education and the
Mini-Mental State Examination score between patients with
DIP (12.5 (3.3) and 27.9 (1.1)), patients with PD (11.8 (4.1)
and 27.8 (1.0)) and controls (13.8 (2.9) and 27.9 (0.9)). Mean
duration of parkinsonism in patients with PD and DIP was 3.9
(SD 3.1) and 1.5 (SD 1.3) years, respectively. The mean follow-
Abbreviations: DIP, drug induced parkinsonism; CCSI, Cross Cultural
Smell Identification; H/M ratio, heart/mediastinum ratio; MIBG,
metaiodobenzylguanidine; PD, Parkinson’s disease; PET, positron emission
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up period in patients with DIP was 5.5 (SD 1.4) months. Details
of the DIP patients and the offending drugs are summarised in
table 1.
The mean CCSI score was significantly greater in patients
with DIP than in those with PD (6.9 (1.6) (range 2–10) vs 4.1
(2.0) (range 0–7); p,0.001); however, the mean CCSI score in
patients with DIP was not statistically different from that of
controls (8.1 (1.9) (range 5–11)) (fig 1A). Fourteen of the 15
patients with DIP had a CCSI score within 2 SDs of the normal
mean, but one score was more than 2 SDs below the normal
mean and fell within the range of the PD patients. The relation
between the CCSI score and H/M ratio is shown in fig 1B. One
patient with DIP (No 15; arrow in fig 1B), whose CCSI score
was more than 2 SDs below the normal range, also exhibited
decreased cardiac MIBG uptake, which fell within the range of
the PD patients (1.24 (0.11)). For the remaining DIP patients
whose CCSI scores were within the normal range, the H/M
ratios were within 2 SDs of the normal mean (2.06 (0.33)).
The 14 patients with DIP whose CCSI scores were within the
normal range exhibited considerable improvement or complete
resolution of parkinsonism on clinical follow-up after with-
drawal of the offending drug, whereas the one DIP patient (No
15) with a significantly lower CCSI score exhibited persistent
parkinsonism (table 1). This patient responded well to
treatment with levodopa, showing a 63% improvement in the
motor unified Parkinson’s disease rating scale.
DISCUSSION
The present study demonstrated that the mean CCSI score was
significantly greater in patients with DIP than in those with PD,
suggesting that an olfactory function test may be useful for
differentiating patients with DIP from those with PD.
Additionally, one DIP patient with a lower CCSI score also
had decreased cardiac MIBG uptake, indicating that the
offending drug may have unmasked clinical manifestations of
parkinsonism in this patient
Depending on the clinical outcome, the patients with DIP
can be classified as DIP unrelated to PD, DIP unmasking PD
and DIP antedating PD.15 According to previous reports,4 5 8
most patients with DIP (70–90%) showed permanent resolu-
tion of parkinsonism after withdrawal of the offending drug,
consistent with DIP unrelated to PD. Interestingly, these
patients had normal 18F-DOPA and cardiac MIBG uptakes,
reflecting no nigrostriatal or cardiac sympathetic dysfunction,
both of which are in PD. The present study demonstrated that
most patients with DIP (93%) had CCSI scores within the
normal range and above the range of PD patient scores, and
showed marked improvement of the parkinsonian features
after withdrawal of the offending drug, suggesting DIP
unrelated to PD. Thus we propose that an olfactory function
test may be a useful tool to detect patients with DIP who are
unrelated to PD.
Although the number of subclinical PD cases in patients with
DIP is small, it is important to detect them, from the viewpoint
of disease prognosis and treatment strategies. It is difficult to
detect a patient with DIP who has subclinical PD on the basis of
the reversibility of the parkinsonian features. The 18F-DOPA
positron emission tomography (PET) and cardiac MIBG scans
may be useful for detecting subclinical PD in patients with DIP.
Burn and Brooks5 studied 13 patients with DIP using 18F-DOPA
PET and identified nigral dysfunction in three patients.
Recently, we conducted cardiac MIBG scans in 20 patients
Table 1 Demographic features in patients with drug induced parkinsonism and their offending drugs
Patient
No
Age (y)/
sex
Offending drug
(duration, mo)
Initial
H&Y
Follow-up
H&Y (mo)*
Patient
No
Age (y)/
sex
Offending drug
(duration, mo)
Initial
H&Y
Follow-up
H&Y (mo)*
1 78/F Levosulpiride (8) 3 1 (5) 9 59/F Levosulpiride (14) 2.5 1 (8)
2 74/F Haloperidone (12) 2.5 0 (4) 10 68/M Levosulpiride (46) 3 1 (6)
3 65/F Flunarizine (6) 3 0 (6) 11 66/F Metoclopramide (8) 2 0 (5)
4 51/F Perphenazine (30) 2.5 0 (8) 12 62/F Risperidone (30) 3 2 (6)
5 73/M Levosulpiride (38) 3 1 (5) 13 76/F Levosulpiride (7) 2 0 (5)
6 63/F Levosulpiride (46) 2.5 0 (3) 14 71/F Levosulpiride (5) 2 0 (6)
7 67/M Perphenazine (2) 2.5 0 (4) 15 73/F Levosulpiride (7) 2 2.5 (5)
8 73/F Levosulpiride (10) 3 0 (7)
H&Y, Hoehn and Yahr.
*The follow-up period from the time the offending drug was discontinued to the time of the last follow-up examination was performed in patients with drug induced
parkinsonism.
Figure 1 (A) Median and quartiles (box plots) as well as 10th and 90th percentiles (whiskers) of individual Cross Cultural Smell Identification (CCSI) scores
in patients with drug induced parkinsonism (DIP), compared with patients with Parkinson’s disease (PD) and controls. (B) The relation between the CCSI score
and the heart to mediastinum ratio (H/M ratio) of 123I-metaiodobenzylguanidine (123I-MIBG) uptake in patients with DIP. Thick line in (A) indicates the mean
value. Broken and continuous lines in (B) indicate the mean of CCSI score and H/M ratio in patients with PD, respectively.
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with DIP and identified cardiac sympathetic dysfunction in two
patients.8 All patients who had abnormal 18F-DOPA and cardiac
MIBG uptakes showed persistent parkinsonism after with-
drawal of the offending drug.
In the present study, one patient with DIP whose CCSI score
lay within the PD range exhibited persistent parkinsonism after
the offending drug was withdrawn. Interestingly, this patient
showed decreased cardiac MIBG uptake, which fell within the
range of PD patients. According to Braak’s neuropathological
staging system for PD,16 the olfactory system may represent one
of the induction sites of neuropathological processes in PD. In
fact, not only olfactory impairment but also cardiac sympathetic
dysfunction were reported in incidental Lewy body disease,17 18
a presymptomatic phase of PD, and these two systems may be
closely coupled in patients with PD.19 Thus this DIP patient may
be in subclinical PD, and the offending drug may aggravate the
potential dopaminergic defect, resulting in the unmasking of
clinical manifestations of parkinsonism.
The olfactory function test is simpler to perform, less invasive
and less expensive than cardiac MIBG or PET scanning. Our
study suggests that an olfactory function test may be a useful
tool to screen for patients with DIP unrelated to PD and to
identify patients with DIP who have subclinical PD. Further
study using functional imaging to detect nigrostriatal function
and long term follow-up are warranted to determine whether
DIP patients with low CCSI scores may also have nigral
pathology.
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